A Prospective, Multi-center, Open-Label, Single-Arm Study of Orelabrutinib in Patients with previously treated indolent non-Hodgkin lymphoma (iNHL) Intolerant of previous BTK Inhibitors
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Orelabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
Most Recent Events
- 09 Dec 2024 According to an InnoCare Pharma media release, updated results from this study were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.
- 09 Dec 2024 Results presented in the InnoCare Pharma Media Release.
- 22 Jun 2024 New trial record